RecruitingNot Applicable

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Egypt100 participantsStarted 2025-07-14

Plain-language summary

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver Exclusion Criteria: Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

What they're measuring

•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Timeframe: 3-6 months after receiving eltombopag

Trial details

NCT IDNCT07093606

SponsorSohag University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-20

Contact for this trial

Peter A Alfy, Resident

01274069691 peter.adel.dola@gmail.com

View on ClinicalTrials.gov More ITP - Immune Thrombocytopenia trials